anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Congenital syphilis is a vertical infection caused by Treponema pallidum. Despite the implementation of preventive strategies during pregnancy, its incidence is increasing, and it constitutes an important public health problem. Most patients with congenital syphilis are asymptomatic; however, a small group may develop severe disease at birth with the need of advanced resuscitation in the delivery room, acute hypoxemic respiratory failure, and hemodynamic instability. Therefore, awareness is needed.
METHODS AND RESULTS: This series describes the clinical course of two late preterm infants with congenital syphilis who developed acute hypoxemic respiratory failure, pulmonary hypertension, and circulatory collapse early after birth. Integrated hemodynamic evaluation with neonatologist-performed echocardiography (NPE) and therapeutic management is provided.
CONCLUSIONS: A comprehensive hemodynamic evaluation including early and serial functional echocardiography in these patients is needed to address the underlying complex pathophysiology and to help to establish accurate treatment.
JATENZO for oral use is provided as a gelatin capsule containing testosterone undecanoate, a fatty-acid ester of testosterone. Testosterone undecanoate is a white to off-white yellow crystalline powder. Testosterone, an androgen, is formed by cleavage of the ester side chain of testosterone undecanoate. 

Testosterone undecanoate is chemically described as 17β-hydroxyandrost-4-en-3-one undecanoate. It has the empirical formula of C30H48O3 and the molecular weight of 456.7. The structural formula for testosterone undecanoate is presented in Figure 1. 

Figure 1: Testosterone Undecanoate

JATENZO capsules are available in three strengths of 158 mg, 198 mg, and 237 mg. 

The 158 mg strength is an opaque red capsule that contains 158 mg of testosterone undecanoate and is imprinted with “158” in white ink. The 198 mg strength is an opaque white capsule that contains 198 mg of testosterone undecanoate and is imprinted with “198” in red ink. The 237 mg strength is an opaque orange capsule that contains 237 mg of testosterone undecanoate and is imprinted with “237” in white ink. All capsule strengths also contain oleic acid, polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), borage seed oil, peppermint oil, and butylated hydroxytoluene as inactive ingredients. 

Gelatin capsule shells are composed of the following inactive ingredients: Gelatin, sorbitol, glycerin, purified water, iron oxide red, FD&C Yellow #6, and titanium dioxide.
The present invention relates to a medicament for treating hernia and a production method thereof. The ingredients of the medicament for treating hernia comprise cotton root, astragalus root, litchi kernel, scorpion, centipede and honey. The shape of a finished medicament is a round pill, a pellet, a capsule or a tablet. The production process comprises drying in the air, crushing, uniformly mixing, sieving, honeyed pill making and packing and has the advantages of unique formulation, scientific medication and simple production process. The prepared medicament can treat hernia with no need of operations and oral administration so as to reduce the pain of patients and thoroughly and radically cure hernia. The present invention provides an ideal Chinese patent medicine for treating hernia and a production method thereof.
PURPOSE: A pharmaceutical composition is provided to suppress NO generation in vivo or in a macrophage and to prevent or treat inflammatory diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating inflammatory diseases contains an aged black garlic extract as an active ingredient. The extract is prepared by hot water extraction. The extract suppresses NO generation in a macrophage or in vivo. The composition additionally contains a pharmaceutically acceptable diluent, excipient, or carrier. A health functional food for preventing or treating inflammatory diseases contains the extract.
The liver organ allocation system was significantly revised in 2002, allowing a more objective prioritization of liver transplant candidates. The revised Model for End Stage Liver Disease (MELD) system is based primarily on laboratory test results. Candidates with MELD scores of less than 15 are considered to be low priority for cadaveric liver transplant and have limited treatment options. Yet patients with low MELD scores may suffer from an array of symptoms associated with liver disease such as fatigue, sleep disturbances, and depression - all of which erode health-related quality of life (HRQoL). No previous studies were found that examined HRQoL in low MELD transplant patients. A better understanding of the HRQoL of these patients will allow clinicians to better meet their needs. Therefore, the aims of the proposed pilot capstone project are to examine HRQoL and to identify demographic and clinical characteristics including liver-disease related symptoms, functional status, perceived social support, biological functioning and mental health associated with HRQoL in pre-liver transplant candidates with low MELD scores. The revised Wilson and Cleary Quality of Life Model will be used to guide the project. Fifty pre-transplant liver candidates with MELD scores \< 15 will be enrolled in the descriptive, cross-sectional pilot study. Participants will complete a written questionnaire measuring perceived HRQoL and clinical characteristics. Descriptive and correlational statistics will be used to analyze the data. Findings from this project will identify trends in factors that contribute to a HRQoL of this population and provide the foundation for a larger future project.
The present invention relates to a novel efficient Chinese medicine for curing appendicitis, which is prepared from raw materials of the following proportion by weight: 25 to 40 of honeysuckle flower, 25 to 40 of patrinia, 12 to 25 of weeping forsythia capsule, 4 to 6 of rhubarb, 12 to 25 of taraxacum, 15 to 30 of coix seed and 12 to 25 of rhizoma corydalis. The medicine is characterized by clearing heat, detoxicating, relieving inflammation, resisting bacteria, removing stasis, removing water retention by hydragogue, subduing inflammation and toxic materials of wounds, dispersing stasis in the intestines, expelling stasis toxin in the intestines, expelling abscess liquid in the intestines, etc.; finally, the active inflammation, the chronic inflammation, the stasis and the pus of the appendix can be expelled, so that the normal functions of the appendix are restored. Patients get rid of the pain of an operation, so the present invention is economical. The present invention is completely composed of natural medicines in the traditional medicine, comprises no chemical medicines or hormone, and has no damage to abdominal organs, good curative effect, obvious effect, short taking period, high safety and high reliability. Periappendicular abscess which is called in the traditional medical science is called appendicitis in the modern medical science. The present invention not only cures appendicitis, but also has favorable curative effect on pulmonary abscess, suppurative tonsillitis, pain caused by periodical abscess and endermic sore, and pain caused by sore tumefaction, and is the medical preparation for curing and preventing appendicitis.
OBJECTIVE: This study aimed to evaluate if placement of transverse cesarean skin incision above or below the overhanging pannus is associated with wound morbidity in morbidly obese patients.
STUDY DESIGN: We identified a cohort of patients with body mass index (BMI) ≥40 kg/m2 undergoing cesarean delivery at a single center from 2017-2020 with complete postpartum records. Data was abstracted after institutional review board exemption, and patients were grouped by low transverse or high transverse skin incision. The primary outcome was a composite of wound infection, fascial dehiscence, incisional hernia, therapeutic wound vacuum, and reoperation. Secondary outcomes included the individual components of the composite, blood transfusion, operative time, and immediate neonatal outcome. T test and χ2 were used for continuous and categorical comparisons. Logistic regression was used to compute adjusted odds ratios for categorical outcomes and linear regression to compare operative times adjusting for factors associated with wound complications and surgical duration respectively.
RESULTS: 328 patients met inclusion criteria: 65 with high transverse (infraumbilical and supraumbilical) and 263 with low transverse (Pfannenstiel) incision. 11% of patients had wound morbidity; high transverse incision was associated with 3.64-fold increased odds of composite wound morbidity (23.1% vs 8%, aOR 3.64, 95% CI 1.52-8.70) and 5.73-fold increased odds of wound infection (13.8% vs. 4.9%, aOR 5.73, 95% CI 1.83-17.96). Time from skin incision to delivery was 1.87 min longer (11.09 vs 14.98 min, β = 1.87, 95% CI 0.17-4.61). There was no significant difference in neonatal outcomes, non-low transverse hysterotomy, or total operative time.
CONCLUSION: High transverse skin incision for cesarean delivery was strongly associated with increased wound morbidity in morbidly obese patients.
Introduction: malnutrition in cancer patients is quite common and can cause various types of harm such as reduced tolerance to therapeutic measures and increased hospital stay. Identification of nutritional risk for these patients may minimize these problems. NUTRISCORE screening has been associated with Global Subjective Assessment Produced by Patient (ASG-PPP) screening, which is considered as the gold standard in cancer patients. No study has evaluated its predictive value in relation to weight loss and length of hospital stay in Brazil. Thus, the present study aims to analyze the NUTRISCORE tool, translated and adapted to the Brazilian population, as a predictor of longer hospital stays, as well as greater hospital weight loss. Methods: first, the NUTRISCORE tool was translated and adapted to the Brazilian population and subsequently applied to patients of both sexes, over 20 years old, admitted to the Cancer Hospital of Pernambuco. The patients were screened and classified as nutritionally "at risk" or "not at risk", their weight was measured at the time of admission and time of discharge from the hospital, and they were followed up throughout their stay to assess their weight loss and length of hospital stay. Results: one hundred and one patients participated in the study, with a higher prevalence of adults and males. The NUTRISCORE showed that patients "at nutritional risk" had a higher risk of greater weight loss (p = 0.001) and longer hospital stay (p = 0.007). Conclusion: NUTRISCORE proved to be a good predictor of longer hospital stay and greater weight loss among hospitalized patients.
Cadmium (Cd) is a prevalent heavy metal contaminant that can cause centrosome amplification (CA) and cancer. Since CA can initiate tumorigenesis, it is plausible that cadmium initiates tumorigenesis via CA. The present study investigated the signaling pathways underlying CA by Cd. Our findings confirmed that sub-toxic concentrations of Cd could induce CA in the HCT116 colon cancer cells, and revealed that reactive oxygen species (ROS), GCLM, CCDC85C and PLK4 were the signaling molecules that formed a pathway of ROS-GCLM-CCDC85C-PLK4. Cd not only increased the protein levels of CCDC85C and PLK4, but also promoted their distribution to the centrosomes. Molecular docking analysis revealed that CCDC85C and PLK4 had the binding potential. Indeed, antibodies against CCDC85C and PLK4 were able to pull down PLK4 and CCDC85C, respectively. Knockdown of CCDC85C decreased the Cd-promoted centrosomal distribution of PLK4. Similarly, knockdown of PLK4 reduced the centrosomal distribution of CCDC85C. Our results suggest that Cd activates ROS-GCLM pathway that triggers the expression of and binding between CCDC85C and PLK4, and promotes the translocation of CCDC85C-PLK4 complex to the centrosomes, which eventually leads to CA.
Participants who are randomized to the control group will receive the usual care that has been established in the ED at UAB hospital. The current usual care at the UAB ED includes a thorough assessment, buprenorphine initiation as appropriate, peer referral, and a written list of buprenorphine clinics. Participants will also receive information about community-based substance use treatment programs. However, these services are at the participant's own discretion to navigate and attend after ED discharge. Participants will be sent survey links to their cell phones and emails to complete self-report questionnaires via REDCap at 1- and 3-month for follow-up assessments. Participants will be reminded via text messages and/or emails to complete the survey twice per day 5 days prior to their follow-up assessments.
Sixty milliliters of 0.25% bupivacaine (150 milligrams), 5ug/mL epinephrine, and ketorolac 30 mg will be deposited at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
Central sensitization (CS) involves an amplification of neural processing within the central nervous system that can result in widespread pain patterns and hypersensitivity to stimuli. The Central Sensitization Inventory (CSI) and various quantitative sensory testing (QST) methods purport to assess clinical markers of CS. The purpose of this systematic review and meta-analysis was to summarize and quantify the associations between total CSI scores and QST measures from previous studies. A systematic search identified 39 unique studies that were deemed eligible for the systematic review and 33 studies for meta-analyses (with 3314 subjects and 154 effect sizes), including five QST modalities: conditioned pain modulation, temporal summation, pressure pain threshold, heat pain threshold, and cold pain threshold. The meta-analysis yielded statistically significant CSI-QST correlations in total subject samples for all five QST modalities. The strongest associations were identified between CSI scores and pain threshold testing, especially pressure pain threshold, in which 51% of effects sizes, from 29 studies and 3071 subjects, were determined to be in a medium to large range.
FIELD: medicine, ophthalmology. SUBSTANCE: the method deals with applying medicinal preparation onto pathological focus. As medicinal preparation one should apply unstable emulsion based upon either sea buckthorn or olive oil containing about 60 - 65 weight% of electrolytic aqueous solution of sodium hypochlorite. One should apply 1 - 2 drops of emulsion mentioned onto pathological focus once or twice daily for 3 - 10 d. In unstable emulsion one should apply electrolytic aqueous solution of sodium hypochlorite at 45 - 80 mg/l concentration. Moreover, as electrolytic aqueous solution of sodium hypochlorite one should apply its buffered solution at 0.35 - 0.45 g (NaH 2 PO 4 ) /100 ml sodium hypochlorite. The method suggested excludes evisceration of an affected eye. EFFECT: higher efficiency of therapy. 2 cl, 4 ex
1288789 Bismuth preparations W J SERFONTEIN 19 Dec 1969 [23 Dec 1968 (2)] 62062/69 Heading A5B A composition for treating peptic ulcers is a modified composition of the type represented by bismuth ammonium citrate cum pepsin (e.g. "Mistura Pepsini et Bismuthi Compositum sine tinctura nucis vomical et acid hydrocyanicum") which has been modified by complex formation or conversion and which in its liquid form, comprises at least 27 mg/ml soluble bismuth derived from bismuth ammonium citrate or its equivalent, at least part of the bismuth being present as a water-soluble protein complex which, on addition of alcohol, precipitates as a thick, gelatinous precipitate which, when subjected to gel filtration at pH 9.0 on a saturated column of cross-linked dextran of a grade suitable for the separation of peptides and globular proteins in the M.U. range 4,000 to 150,000, yields two peaks of which the first includes over 10% of the said bismuth. A ligand-forming dye, e.g. cochineal, carmine, or azo-rubrium may also be present. The invention also comprises a method of preparing the bismuth-containing material by precipitation of a gelatinous precipitate from the known preparations of the type abovementioned and subjecting it to gel filtration to obtain the required material.
AIM: This study aimed to investigate the separate and joint associations of triglyceride-glucose (TyG) index accumulation and variability with prediabetes and diabetes risk.
METHODS: Health check-up participants who underwent 3 sequential health examinations during 2012-2016 and were followed up from 2017 to 2021 were enrolled and categorized into two subcohorts: (a) progression from normoglycaemia to prediabetes subcohort (n = 9373) and (b) progression from prediabetes to diabetes subcohort (n = 4563). Cumulative TyG (cumTyG) and TyG variability from Exams 1-3 were the exposures of interest in our study. The outcomes were newly incident prediabetes or diabetes.
RESULTS: In the prediabetes development subcohort, 2,074 participants developed prediabetes over a 2.42-year follow-up. Higher cumTyG (HR, 2.02; 95 % CI, 1.70-2.41), but not greater TyG variability alone, was significantly associated with increased prediabetes risk. In the diabetes development subcohort, 379 participants developed diabetes over a 3.0-year follow-up. Higher cumTyG (HR, 3.54; 95 % CI, 2.29-5.46), but not greater TyG variability alone, was significantly associated with increased diabetes risk. The "cumTyG+variability" combination had the highest predictive value for prediabetes and diabetes beyond a single baseline TyG measurement.
CONCLUSION: Higher cumTyG exposure independently predicts prediabetes and diabetes incidence. Coexisting cumTyG and variability could further yield incrementally greater risks.
FIELD: experimental pharmacology. SUBSTANCE: 5-isopropyl-1-phenyl-2-(B-diethylaminoethyl)-mercapto-3,4-di- hydropyrilenedine-4-ol-6-one chlorohydrate (ТБ-28) inhibits lipid peroxidation in systems in vitro and in vivo. Antioxidant activity (AOA) of ТБ-28 is measured at condition of induction of iron/ascorbate dependent lipid peroxidation in the medium of yolk lipoproteins in vitro and in vivo at induction of lipid peroxidation by administration of carbon tetrachloride to rats. For AOA detection of ТБ-28 in vitro experiments its concentration in incubation medium is maintained at the range 10 -6 -10 -4 mole/l, and in vivo experiments ТБ-28 is administrated to rats by intraperitoneally as an aqueous solution at the dose from 10 to 50 mg/kg animal mass 2 hr before CCl 4  administration for 3 days. AOA of ТБ-28 exceeds that of tocopherol in vitro experiments. EFFECT: high antioxidant activity of preparation proposed. 3 dwg, 1 tbl
Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Duloxetine Delayed-release Capsules and should counsel them in its appropriate use. A patient Medication Guide is available for Duloxetine Delayed-release Capsules. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide before starting Duloxetine Delayed-release Capsules and each time their prescription is renewed, and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Duloxetine Delayed-release Capsules.
Administer one dose of ZOMIG Nasal Spray 5 mg for the treatment of acute migraine. If the headache returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 10 mg in any 24-hour period.

In controlled clinical trials, single doses of 5 mg of zolmitriptan nasal spray were administered into one nostril and were effective for the treatment of acute migraines in adults.

Individuals may vary in response to ZOMIG Nasal Spray. The pharmacokinetics of a 5 mg nasal spray dose is similar to the 5 mg oral formulations. Doses lower than 5 mg can only be achieved through the use of an oral formulation. The choice of dose, and route of administration should therefore be made on an individual basis.

The safety of treating an average of more than four headaches in a 30-day period has not been established.
<P>PROBLEM TO BE SOLVED: To provide a transdermal transport device capable of the accurate insertion of needles without pain and capable of the programmable control.  <P>SOLUTION: The transdermal transport device 10 includes a reservoir 46 for holding a substance including a specific component, and an array of needles 12. The array of needles 12 makes it easy to transport the substance into the reservoir 46 through the needles 12 and to transport the substance from the reservoir 46 to the outside through the needles 12 because the needles have bores liquid-communicating with the reservoir 46. The transport device further includes a first actuator 24 to drives the array of needles into the living body, and a second actuator 38 to transport the substance between the reservoir 46 and a target through the needles 12 by means of the pumping action. The first actuator 24 is a reversible actuator to act in the reverse direction, so that the needles can be withdrawn from the living body.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Protein targets for disease intervention through inhibition of nucleic acid metabolism are disclosed. Novel polypeptides for one such target, DNA-dependent ATPase A, and novel polynucleotides encoding DNA-dependent ATPase A are disclosed. Phosphoaminoglycoside compounds which act on such protein targets to inhibit nucleic acid metabolism. In addition, screening assays for identifying compounds that inhibit nucleic acid-dependent ATPase activity, including, but not limited to, DNA-dependent ATPase A, are disclosed. Such compounds are useful in the treatment of diseases, including but not limited to cancer and infectious disease, through disruption of nucleic acid metabolism and induction of apoptosis. Moreover, methods for prevention and treatment of diseases including, but not limited to cancer and infectious disease are disclosed.